RxDoctor Payments DataLook up a doctor →

John Hrom, MD

Hematology & Oncology · Hattiesburg, MSNPI 1134238496

Payments from drug & device makers

$10,036,470in general payments, 2019–2025

Across 1,413 payments — averaging $7102.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3.6M
  • Merck$2M
  • Beigene, Ltd.$1.9M
  • AbbVie$424K
  • Incyte Corporation$377K
  • Regeneron$331K
  • plus $1.4M from 54 others
$953in research payments, 2019–2025

Across 8 payments — averaging $119.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$672
  • AbbVie$280

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen47$3,582,977
Merck232$2,037,539
Beigene, Ltd.131$1,879,314
AbbVie85$423,811
Incyte Corporation141$377,043
Regeneron102$330,526
Bristol Myers Squibb37$273,360
Janssen Research & Development, LLC30$225,770
Beone Medicines Ltd.9$217,233
E.r. Squibb & Sons, L.L.C.72$214,545
Heron Therapeutics, Inc.14$129,756
Sanofi US Services Inc.15$78,589
Beone Medicines USA, Inc.11$61,869
Beigene USA, Inc.20$48,556
Pfizer53$46,738
AstraZeneca(2 entities)31$36,898
Eli Lilly4$21,890
Ipsen Bioscience Inc.2$11,450
Macrogenics, Inc.4$9,375
Biontech SE3$8,194
Spectrum Pharmaceuticals Inc.5$6,176
Helsinn Healthcare SA1$4,336
Portola Pharmaceuticals, LLC1$2,927
Gilead(2 entities)33$1,223
Johnson & Johnson(2 entities)46$764
Novartis33$559
Astellas Pharma US Inc21$458
Genentech USA, Inc.26$429
Sanofi23$403
Exelixis Inc.12$315
GSK13$254
Jazz Pharmaceuticals Inc.10$220
Pharmacyclics LLC, An Abbvie Company6$209
Octapharma USA, Inc.9$195
Daiichi Sankyo Inc.8$163
Eisai Inc.9$158
Bayer6$143
Myriad Genetic Laboratories, Inc.4$140
Karyopharm Therapeutics Inc.4$132
Ipsen Biopharmaceuticals, Inc7$130
Takeda Pharmaceuticals U.S.A., Inc.7$129
Puma Biotechnology, Inc.8$105
Tersera Therapeutics LLC3$96
Deciphera Pharmaceuticals Inc.4$89
ADC Therapeutics America, Inc.3$85
Seagen Inc.4$82
Blueprint Medicines Corporation4$71
Springworks Therapeutics, Inc.4$68
Verastem, Inc.4$59
EMD Serono, Inc.4$59
Regeneron Healthcare Solutions, Inc.3$55
Stemline Therapeutics Inc.2$54
Sumitomo Pharma America, Inc.1$52
G1 Therapeutics, Inc.3$51
Sanofi-aventis U.S. LLC3$49
Mirati Therapeutics, Inc.3$45
Rigel Pharmaceuticals, Inc.3$44
Taiho Oncology, Inc.2$43
Pharmacosmos Therapeutics Inc.2$38
Foundation Medicine, Inc.2$37

How this compares

$10,036,470 in reported general payments places this provider in the 95th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi →

Medicare billing

Part B allowed, 2024
$7,121,267
Medicare patients
969
Services billed
416,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Hattiesburg

See the full list for Mississippi →

Where these figures come from

Is this you, or does something look wrong? →